Ken Griffin Nkarta, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$5.27 - $10.82 $24,768 - $50,854	-4,700 Reduced 24.1%	14,800 $87,000
Q1 2024 May 15, 2024	BUY	$5.59 - $15.71 $53,664 - $150,816	9,600 Added 96.97%	19,500 $210,000
Q4 2023 Feb 14, 2024	BUY	$1.31 - $6.6 $11,266 - $56,760	8,600 Added 661.54%	9,900 $65,000
Q3 2023 Nov 14, 2023	SELL	$1.39 - $2.29 $9,591 - $15,801	-6,900 Reduced 84.15%	1,300 $1,000
Q2 2023 Aug 14, 2023	SELL	$2.19 - $5.17 $3,066 - $7,238	-1,400 Reduced 14.58%	8,200 $17,000
Q1 2023 May 15, 2023	SELL	$3.37 - $6.3 $18,872 - $35,280	-5,600 Reduced 36.84%	9,600 $34,000
Q4 2022 Feb 14, 2023	SELL	$5.14 - $14.35 $208,684 - $582,610	-40,600 Reduced 72.76%	15,200 $91,000
Q3 2022 Nov 14, 2022	SELL	$12.27 - $18.39 $549,696 - $823,872	-44,800 Reduced 44.53%	55,800 $734,000

124

66.2M

142K

43.1K

Ticker NKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,656,800
Market Cap $157M
Description
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the sur...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.